← All trials
NCT04404517
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2019
- Primary completion
- Jun 30, 2020
- Completion date
- Oct 30, 2020
- First posted
- May 27, 2020
- Last posted
- May 27, 2020
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Autonomous University of MadridLead sponsor
- Autonomous University of MadridReponsible party - principal investigator
- Hospital La PazStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.